These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 30976568)

  • 1. The rational and benefits of the second look transurethral resection of the bladder for T1 high grade bladder cancer.
    Soria F; Marra G; D'Andrea D; Gontero P; Shariat SF
    Transl Androl Urol; 2019 Feb; 8(1):46-53. PubMed ID: 30976568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?
    Soria F; D'Andrea D; Moschini M; Giordano A; Mazzoli S; Pizzuto G; Hurle R; Colombo R; Briganti A; Altieri V; Shariat SF; Gontero P
    Urol Oncol; 2020 Mar; 38(3):77.e1-77.e7. PubMed ID: 31526650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Is a routine second transurethral resection of the bladder still necessary after hexaminolévulinate photodynamic diagnosis-assisted TURBT?].
    Doisy L; Walz J; Fakhfakh S; Rybikowski S; Koskas Y; Gravis G; Pignot G
    Prog Urol; 2019; 29(6):332-339. PubMed ID: 31104952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current concept of transurethral resection of bladder cancer: from re-transurethral resection of bladder cancer to en-bloc resection.
    Schraml J; Silva JDC; Babjuk M
    Curr Opin Urol; 2018 Nov; 28(6):591-597. PubMed ID: 30102624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial.
    D'Andrea D; Soria F; Hurle R; Enikeev D; Kotov S; Régnier S; Xylinas E; Lusuardi L; Heidenreich A; Cai C; Frego N; Taraktin M; Ryabov M; Gontero P; Compérat E; Shariat SF;
    Eur Urol Oncol; 2023 Oct; 6(5):508-515. PubMed ID: 37543464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review.
    Cumberbatch MGK; Foerster B; Catto JWF; Kamat AM; Kassouf W; Jubber I; Shariat SF; Sylvester RJ; Gontero P
    Eur Urol; 2018 Jun; 73(6):925-933. PubMed ID: 29523366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis?
    Beijert IJ; Hentschel AE; Bründl J; Compérat EM; Plass K; Rodríguez O; Subiela Henríquez JD; Hernández V; de la Peña E; Alemany I; Turturica D; Pisano F; Soria F; Čapoun O; Bauerová L; Pešl M; Bruins HM; Runneboom W; Herdegen S; Breyer J; Brisuda A; Calatrava A; Rubio-Briones J; Seles M; Mannweiler S; Bosschieter J; Kusuma VRM; Ashabere D; Huebner N; Cotte J; Contieri R; Mertens LS; Claps F; Masson-Lecomte A; Liedberg F; Cohen D; Lunelli L; Cussenot O; El Sheikh S; Volanis D; Côté JF; Rouprêt M; Haitel A; Shariat SF; Mostafid AH; Nieuwenhuijzen JA; Zigeuner R; Dominguez-Escrig JL; Hacek J; Zlotta AR; Burger M; Evert M; Hulsbergen-van de Kaa CA; van der Heijden AG; Kiemeney LALM; Soukup V; Molinaro L; Gontero P; Llorente C; Algaba F; Palou J; N'Dow J; Ribal MJ; van der Kwast TH; Babjuk M; Sylvester RJ; van Rhijn BWG
    Int Urol Nephrol; 2024 Apr; 56(4):1323-1333. PubMed ID: 37980689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do we need a re-TUR after en bloc resection of T1 stage bladder cancer?
    Levy S; Péricart S; Bajeot AS; Fakhfakh S; Lesourd M; Soulié M; Pignot G; Roumiguié M
    World J Urol; 2024 Aug; 42(1):475. PubMed ID: 39115589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [T1 high-grade bladder cancer - value of second operation with prognostuic parameters of first operation: analysis of 167 cases].
    Lazica DA; Böttcher S; Degener S; von Rundstedt FC; Brandt AS; Roth S; Störkel S; Mathers MJ
    Aktuelle Urol; 2013 Mar; 44(2):124-8. PubMed ID: 23580383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative outcomes of transurethral resection for t1 bladder tumors: quality evaluation based on patient, tumor and surgeon criteria.
    Bebane S; Denize J; Goujon A; Meria P; Verine J; Mongiat-Artus P; Desgrandchamps F; Masson-Lecomte A
    World J Urol; 2021 Nov; 39(11):4159-4165. PubMed ID: 34160681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology.
    Neuzillet Y; Methorst C; Schneider M; Lebret T; Rouanne M; Radulescu C; Molinie V; Dreyfus JF; Pelcat V; Botto H
    Urol Oncol; 2014 Nov; 32(8):1135-40. PubMed ID: 25023786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Narrow-band imaging (NBI) and white light (WLI) transurethral resection of the bladder in the treatment of non-muscle-invasive bladder cancer.
    Montanari E; de la Rosette J; Longo F; Del Nero A; Laguna P
    Arch Ital Urol Androl; 2012 Dec; 84(4):179-83. PubMed ID: 23427740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The need for re-TUR of the bladder in non-muscle invasive bladder cancer: risk factors of tumor persistence in re-TUR specimens.
    Husillos Alonso A; Rodríguez Fernández E; Herranz Amo F; López López E; Aragón Chamizo J; Ramírez Martínez D; Durán Merino R; Hernández Fernández C
    Minerva Urol Nefrol; 2014 Dec; 66(4):233-40. PubMed ID: 25531192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transurethral resection of bladder tumor and the need for re-transurethral resection of bladder tumor: time to change our practice?
    Soria F; Giordano A; Gontero P
    Curr Opin Urol; 2020 May; 30(3):370-376. PubMed ID: 32205809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing recurrence in non-muscle-invasive bladder cancer by systematically implementing guideline-based recommendations: effect of a prospective intervention in primary bladder cancer patients.
    Sörenby A; Baseckas G; Bendahl PO; Brändstedt J; Håkansson U; Nilsson S; Patschan O; Tinzl M; Wokander M; Liedberg F; Gudjonsson S
    Scand J Urol; 2019; 53(2-3):109-115. PubMed ID: 31064253
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cost-effectiveness of transurethral resection of the bladder with blue light in patients with non muscle invasive bladder cancer in France].
    Rouprêt M; Malavaud B; Molinier L; Leleu H; Blachier M; Marteau F
    Prog Urol; 2015 Apr; 25(5):256-64. PubMed ID: 25605343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
    Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does repeat transurethral resection of bladder tumor influence the diagnosis and prognosis of T1 bladder cancer? A systematic review and meta-analysis.
    Lin L; Guo X; Ma Y; Zhu J; Li X
    Eur J Surg Oncol; 2023 Jan; 49(1):29-38. PubMed ID: 35752497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.